Clinical Trial

Disease: Relapsed or Refractory Multiple Myeloma, MM, (NCT05722418)

Disease info:

Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the centre of most bones. Multiple myeloma is characterised by abnormalities in plasma cells, a type of white blood cell. In myeloma, these abnormal cells multiply uncontrollably, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumours within the bone, causing bone pain and an increased risk of fractures.

Relapsed myeloma refers to when a patient had active treatment that their disease responded to, went off treatment and then the disease came back. 

Refractory myeloma is a disease that is progressing despite active treatment.

 

Frequency:
An estimated 36,110 people will be diagnosed with MM in 2025.
Official title:
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Who:

Contact

Name: Kellie McWilliams, MS

Phone Number: 510-982-6030 ext 3

Email: clinicaltrials@cariboubio.com

 

Sponsor:

Caribou Biosciences

Partners:
Locations:

United States, Alabama

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

 

United States, Colorado

CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora, Colorado, United States, 80045

 

United States, Florida

Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, United States, 33136

 

United States, Kentucky

University of Kentucky/ Markey Cancer Center, Lexington, Kentucky, United States, 40536

 

United States, Massachusetts 

Massachusetts General, Boston, Massachusetts, United States, 220071



United States, New Jersey 

John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States, 07601



United States, New York 

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

 

United States, North Carolina

Levine Cancer Institute, Charlotte, North Carolina, United States, 28204

Duke University Health System (DUHS), Durham, North Carolina, United States, 27705



United States, Ohio 

Oncology Hematology Care, Inc, Cincinnati, Ohio, United States, 45236

Cleveland Clinic, United States, Cleveland, Ohio, United States, 44195



United States, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee, United States, 37203



United States, Texas 

University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030

 

United States, Utah

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States, 84112

 

United States, Virginia

Virginia Commonwealth University, Richmond, Virginia, United States, 23235

 

United States, Wisconsin 

Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Study start:
Feb. 6, 2023
Enrollment:
50 participants
Gene editing method:
Cas12a chRDNA (CRISPR hybrid RNA-DNA)
Type of edit:
Gene knock-out, gene knock-in
Gene:
B-cell maturation antigen (BCMA) T Cell Receptor Alpha Constant (TRAC) beta-2 microglobulin (B2M)
Delivery method:
Adeno-associated virus (AAV)
Trial link:
https://www.clinicaltrials.gov/ct2/show/NCT05722418
Safety updates:

(05-04-2023) CRISPR Clinical Trial Updates From Caribou Biosciences

(04-04-2023) Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

(29-03-2023) Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

(21-11-2022) Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Other links:

LinkCRISPR Clinical Trial Updates From Caribou Biosciences (April 2023)

Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Last updated: May. 20, 2025
close
Search CRISPR Medicine